Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team.
暂无分享,去创建一个
Courtney Crim | Edwin K Silverman | Bartolome Celli | Ruth Tal-Singer | Emiel F M Wouters | Alvar Agusti | Per Bakke | L. Edwards | E. Silverman | B. Celli | J. Vestbo | P. Bakke | D. Lomas | B. Miller | A. Agustí | E. Wouters | H. Coxson | W. MacNee | J. Yates | S. Rennard | R. Tal-Singer | P. Calverley | C. Crim | N. Locantore | Peter M A Calverley | Stephen I Rennard | Jørgen Vestbo | David A Lomas | Harvey Coxson | Lisa D Edwards | William MacNee | Julie C Yates | Nicholas Locantore | Bruce Miller | W. Macnee
[1] J. Vestbo,et al. Persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort. , 2014, Respiratory medicine.
[2] J. Connett,et al. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.
[3] Donavan T. Cheng,et al. Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.
[4] L. Edwards,et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. , 2013, Respiratory medicine.
[5] B. Nordestgaard,et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. , 2013, JAMA.
[6] R. Casaburi,et al. The COPD Biomarker Qualification Consortium (CBQC) , 2013, COPD.
[7] Courtney Crim,et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. , 2013, The Lancet. Respiratory medicine.
[8] L. Edwards,et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. , 2013, American journal of respiratory and critical care medicine.
[9] F. Martinez,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.
[10] Satoshi Konno,et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.
[11] B. Nordestgaard,et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.
[12] L. Edwards,et al. Clinical impact of anaemia in patients with chronic obstructive pulmonary disease: Results from ECLIPSE study , 2012 .
[13] L. Edwards,et al. Coronary artery calcification in COPD is associated with adverse functional assessments and mortality , 2012 .
[14] L. Edwards,et al. The minimal clinically important difference (MCID) for the six minute walk (6MW) test in COPD in relation to death , 2012 .
[15] P. Jones,et al. GOLD assessment of COPD patients: Impact of symptoms assessment choice , 2012 .
[16] L. Edwards,et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease , 2012, Thorax.
[17] Courtney Crim,et al. Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.
[18] L. Edwards,et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.
[19] L. Edwards,et al. Soluble Receptor For Advanced Glycation Endproducts (sRAGE) Is A Biomarker Of Emphysema In The ECLIPSE Cohort , 2012, ATS 2012.
[20] Marleen de Bruijne,et al. Factors influencing the decline in lung density in a Danish lung cancer screening cohort , 2012, European Respiratory Journal.
[21] L. Edwards,et al. Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. , 2012, Journal of the American Medical Directors Association.
[22] L. Edwards,et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort , 2011, Respiratory research.
[23] Ciro Casanova,et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. , 2011, American journal of respiratory and critical care medicine.
[24] L. Edwards,et al. Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.
[25] J. Vestbo,et al. Fatigue components in COPD patients and controls using the FACIT-F scale; data from ECLIPSE study , 2011 .
[26] L. Edwards,et al. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. , 2011, Respiratory medicine.
[27] L. Edwards,et al. Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. , 2011, Academic radiology.
[28] L. Edwards,et al. One-Year Stability Of Quadriceps Muscle Strength In Patients With COPD: An Eclipse Sub Study , 2011, ATS 2011.
[29] L. Edwards,et al. Reduced 6MWD Is Associated With Increased Mortality And Exacerbation-Related Hospitalization In COPD: The Eclipse Study , 2011, ATS 2011.
[30] J. Wedzicha,et al. Risk Factors And Mortality Associated With Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Exacerbations During The 3-Year Follow-Up In The Evaluation Of COPD Longitudinally To Identify Predictive Surrogate Endpoints (Eclipse) Cohort , 2011, ATS 2011.
[31] L. Edwards,et al. Measurement Of Physical Activity In Patients With COPD In A Multicenter Setting: Compliance And Associations With Clinical Characteristics Of The Disease , 2011, ATS 2011.
[32] Bram van Ginneken,et al. CT-quantified emphysema in male heavy smokers: association with lung function decline , 2011, Thorax.
[33] J. Vestbo,et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. , 2011, American journal of respiratory and critical care medicine.
[34] P. Calverley,et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study , 2011, The clinical respiratory journal.
[35] J. Vestbo,et al. Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. , 2010, American journal of respiratory and critical care medicine.
[36] J. Wedzicha,et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.
[37] Edwin K Silverman,et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.
[38] Edwin K Silverman,et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.
[39] R. Rodríguez-Roisín,et al. Frequent Chronic Obstructive Pulmonary Disease Exacerbators: How Much Real, How Much Fictitious? , 2010, COPD.
[40] L. Edwards,et al. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. , 2010, Respiratory medicine.
[41] Niels H Chavannes,et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. , 2009, American journal of respiratory and critical care medicine.
[42] M. Decramer,et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial , 2009, The Lancet.
[43] Dave Singh,et al. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. , 2009, Respiratory medicine.
[44] Ulrike Held,et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index , 2009, The Lancet.
[45] C. Jenkins,et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study , 2009, Respiratory research.
[46] A. Dirksen,et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in α1-antitrypsin deficiency , 2009, European Respiratory Journal.
[47] J. Wedzicha,et al. Comparison of Perceived Exacerbation Frequency in COPD Patients and Actual Number of Exacerbations – Data from the ECLIPSE Study. , 2009, ATS 2009.
[48] L. Edwards,et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD , 2009, European Respiratory Journal.
[49] J. Vestbo,et al. P147 DISCRIMINATING EFFECTS OF MUSCLE WASTING WITH LOW AND NORMAL BMI IN COPD , 2009 .
[50] J. Wedzicha,et al. Diagnosis of COPD Exacerbations and Their Distribution Based on GOLD Severity Stages. Data from the Evaluation of COPD Longitudinally To Identify Predictive Surrogate Endpoints (ECLIPSE) Study , 2009, ATS 2009.
[51] M. Decramer,et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.
[52] L. Edwards,et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort , 2008, Thorax.
[53] P. Calverley,et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.
[54] Liam Ck. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008 .
[55] W. MacNee,et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.
[56] K. Rabe,et al. Complex chronic comorbidities of COPD , 2008, European Respiratory Journal.
[57] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[58] S. Bojesen,et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[59] T. Ng,et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. , 2007, Archives of internal medicine.
[60] B. Celli,et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients: Eur Respir J 2006 Feb 2; published online ahead of print as doi:10.1183/09031936.06.00109605 , 2006 .
[61] P. Gevenois,et al. Pulmonary emphysema: objective quantification at multi-detector row CT--comparison with macroscopic and microscopic morphometry. , 2006, Radiology.
[62] S. Bojesen,et al. C-reactive Protein as a Predictor of Prognosis in COPD. , 2006 .
[63] C. Lenfant,et al. Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .
[64] N. Anthonisen,et al. Bronchodilator response in the lung health study over 11 yrs , 2005, European Respiratory Journal.
[65] A. Agustí,et al. COPD, a multicomponent disease: implications for management. , 2005, Respiratory medicine.
[66] Jan Stolk,et al. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.
[67] Ciro Casanova,et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.
[68] S. Spencer,et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.
[69] T. Seemungal,et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease , 2002, Thorax.
[70] B. Nordestgaard,et al. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.
[71] N. Anthonisen,et al. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. , 2001, American journal of respiratory and critical care medicine.
[72] H A Vrooman,et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. , 1999, American journal of respiratory and critical care medicine.
[73] A. Dirksen,et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.
[74] W. Bailey,et al. Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .
[75] N. Pride,et al. A "splitting" look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. , 1991, The European respiratory journal.
[76] R. Peto,et al. The natural history of chronic airflow obstruction. , 1977, British medical journal.
[77] G. Little,et al. The natural history of chronic bronchitis and emphysema , 1979 .
[78] C. Fletcher. The Natural history of chronic bronchitis and emphysema: An eight-year study of early chronic obstructive lung disease in working men in London , 1976 .